NASDAQ:VERU Veru (VERU) Stock Price, News & Analysis → Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad) Free VERU Stock Alerts $0.89 -0.04 (-4.31%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$0.87▼$0.9750-Day Range$0.83▼$1.7952-Week Range$0.36▼$1.92Volume1.62 million shsAverage Volume2.34 million shsMarket Capitalization$130.10 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Veru alerts: Email Address Veru MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside350.0% Upside$4.00 Price TargetShort InterestHealthy8.20% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 3 Articles This WeekInsider TradingSelling Shares$250,075 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector554th out of 913 stocksPharmaceutical Preparations Industry261st out of 429 stocks 3.5 Analyst's Opinion Consensus RatingVeru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVeru has only been the subject of 4 research reports in the past 90 days.Read more about Veru's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.20% of the outstanding shares of Veru have been sold short.Short Interest Ratio / Days to CoverVeru has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Veru has recently decreased by 5.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeru does not currently pay a dividend.Dividend GrowthVeru does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERU. Previous Next 2.1 News and Social Media Coverage News SentimentVeru has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Veru this week, compared to 2 articles on an average week.Search InterestOnly 23 people have searched for VERU on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Veru to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veru insiders have sold 1,397.54% more of their company's stock than they have bought. Specifically, they have bought $16,699.00 in company stock and sold $250,075.00 in company stock.Percentage Held by Insiders14.20% of the stock of Veru is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.16% of the stock of Veru is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Veru's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Veru are expected to decrease in the coming year, from ($0.27) to ($0.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veru is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veru is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeru has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Veru's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Veru Stock (NASDAQ:VERU)Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.Read More VERU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERU Stock News HeadlinesMay 25, 2024 | insidertrades.comInsider Selling: Veru Inc. (NASDAQ:VERU) CEO Sells 63,379 Shares of StockMay 18, 2024 | insidertrades.comMitchell Shuster Steiner Sells 28,066 Shares of Veru Inc. (NASDAQ:VERU) StockJune 10 at 8:30 AM | globenewswire.comVeru to Present at the American Diabetes Association's 84th Scientific SessionsJune 6, 2024 | americanbankingnews.comVeru (NASDAQ:VERU) Shares Cross Above 200 Day Moving Average of $0.85May 22, 2024 | finance.yahoo.comIndividual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%May 22, 2024 | globenewswire.comVeru to Present at the Jefferies Global Healthcare ConferenceMay 17, 2024 | investing.comVeru Inc. CEO sells over $246k in company stockMay 17, 2024 | investing.comVeru Inc. executive buys $9,999 in company stockMay 15, 2024 | globenewswire.comVeru Announces Steven B. Heymsfield M.D.May 14, 2024 | globenewswire.comVeru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology WeekMay 14, 2024 | markets.businessinsider.comBuy Rating for Veru Inc. on Promising Enobosarm Trials and Strategic Market PositioningMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on Veru Amid Strong Clinical Prospects and Solid Financial PositionMay 9, 2024 | finance.yahoo.comVeru Inc (VERU) Q2 2024 Earnings Call Transcript Highlights: Strategic Focus and Financial RecoveryMay 8, 2024 | msn.comVERU Stock Earnings: Veru Misses EPS, Beats Revenue for Q2 2024May 8, 2024 | finanznachrichten.deVeru Inc.: Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical ProgramMay 8, 2024 | finance.yahoo.comVeru Inc. (VERU) Fiscal 2024 Q2 Earnings: Clinical Advances Amid Financial StrainsMay 8, 2024 | globenewswire.comVeru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical ProgramMay 7, 2024 | msn.comVeru Q2 2024 Earnings PreviewMay 6, 2024 | benzinga.comCritical Insights From Veru Analyst Ratings: What You Need To KnowMay 3, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)May 2, 2024 | globenewswire.comVeru to Present at the GLP-1 Based Therapeutics SummitMay 1, 2024 | globenewswire.comVeru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024April 30, 2024 | globenewswire.comVeru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight LossApril 30, 2024 | finance.yahoo.comPalisade Capital Management Welcomes Chris Mashia to Small Cap Core and Smid Cap Core Equity StrategiesApril 25, 2024 | globenewswire.comVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11See More Headlines Receive VERU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/12/2024Next Earnings (Estimated)8/08/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPersonal Products Current SymbolNASDAQ:VERU CUSIP31446210 CIK863894 Webwww.veruhealthcare.com Phone(305) 509-6897Fax312-595-9122Employees189Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+339.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,150,000.00 Net Margins-265.27% Pretax Margin-283.63% Return on Equity-130.13% Return on Assets-67.82% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.22 Sales & Book Value Annual Sales$16.30 million Price / Sales8.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book4.14Miscellaneous Outstanding Shares146,380,000Free Float125,597,000Market Cap$133.31 million OptionableOptionable Beta-0.39 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Mitchell S. Steiner F.A.C.S. (Age 63)M.D., Chairman, President & CEO Comp: $885.32kDr. Harry Fisch F.A.C.S. (Age 65)M.D., Vice Chairman & Chief Corporate Officer Ms. Michele Greco (Age 65)CFO & Chief Administrative Officer Comp: $493.7kDr. K. Gary Barnette Ph.D. (Age 56)Chief Scientific Officer Comp: $676.27kMr. Samuel FischExecutive Director of Investor Relations & Corporate CommunicationsMr. Michael J. PurvisExecutive VP, General Counsel & Corporate Strategy and SecretaryMr. Kevin J. Gilbert CPAJ.D., Executive Vice President of Corporate DevelopmentMr. Martin Tayler (Age 55)Executive Vice President of FC2 Global Operations Comp: $180.51kMr. Philip R. Greenberg J.D.Executive VP & Deputy General CounselDr. Domingo Rodriguez M.D. (Age 62)Executive Vice President of Global Clinical Operations More ExecutivesKey CompetitorsNature's Sunshine ProductsNASDAQ:NATRMedifastNYSE:MEDEstée Lauder CompaniesNYSE:ELInter ParfumsNASDAQ:IPARPrestige Consumer HealthcareNYSE:PBHView All CompetitorsInsiders & InstitutionsMitchell Shuster SteinerSold 63,379 sharesTotal: $77,956.17 ($1.23/share)Cetera Advisors LLCBought 47,341 shares on 5/24/2024Ownership: 0.032%K Gary BarnetteBought 5,000 shares on 5/24/2024Total: $6,700.00 ($1.34/share)Mitchell Shuster SteinerSold 6,504 sharesTotal: $9,040.56 ($1.39/share)Mitchell Shuster SteinerSold 28,066 sharesTotal: $37,047.12 ($1.32/share)View All Insider TransactionsView All Institutional Transactions VERU Stock Analysis - Frequently Asked Questions Should I buy or sell Veru stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VERU shares. View VERU analyst ratings or view top-rated stocks. What is Veru's stock price target for 2024? 4 analysts have issued 1 year price objectives for Veru's stock. Their VERU share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 350.0% from the stock's current price. View analysts price targets for VERU or view top-rated stocks among Wall Street analysts. How have VERU shares performed in 2024? Veru's stock was trading at $0.72 at the beginning of the year. Since then, VERU shares have increased by 23.4% and is now trading at $0.8888. View the best growth stocks for 2024 here. When is Veru's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our VERU earnings forecast. How were Veru's earnings last quarter? Veru Inc. (NASDAQ:VERU) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.02. The company had revenue of $4.14 million for the quarter, compared to the consensus estimate of $3 million. Veru had a negative trailing twelve-month return on equity of 130.13% and a negative net margin of 265.27%. What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV). Who are Veru's major shareholders? Veru's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.22%), Rosalind Advisors Inc. (3.07%), Ikarian Capital LLC (0.65%), Alpine Global Management LLC (0.49%), 180 Wealth Advisors LLC (0.12%) and Choreo LLC (0.06%). Insiders that own company stock include Harry Fisch, K Gary Barnette, Lucy Lu, Mario Eisenberger and Mitchell Shuster Steiner. View institutional ownership trends. How do I buy shares of Veru? Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VERU) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredPotentially Pocket $767/Day with AIWhat if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veru Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veru With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.